Orphan Drugs Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

The report covers Global Orphan Drug Market Companies and it is segmented by Drug Type (Biological, Non-biological), Top Selling Drugs (Revlimid, Darzalex, Rituxan, Tafinlar, Ninlaro, Imbruvica, Myozyme, Soliris, Jakafi, Kyprolis, Other Top Selling Drugs), Disease Type (Oncology, Hematology, Neurology, Cardiovascular, Other Disease Types) and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market size and forecasts are provided in terms of value (USD million) for all the above segments.

Orphan Drugs Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

Orphan Drugs Industry Overview

The orphan drugs market is moderately competitive. In terms of market share, a few of the major players currently dominate the market. With the rising number of diseases and an increasing number of cases each year, a few smaller players are entering the market and holding a substantial share. Some of the market players include Celgene Corporation, Takeda Pharmaceutical Company Limited, Novartis AG, Johnson & Johnson, F. Hoffmann-La Roche Ltd and others.

Orphan Drugs Market Leaders

  1. Takeda Pharmaceutical Company Limited

  2. Novartis AG

  3. Johnson & Johnson

  4. F. Hoffmann-La Roche Ltd

  5. Bristol-Myers Squibb Company (Celgene Corporation)

  6. *Disclaimer: Major Players sorted in no particular order
Orphan Drugs Market Concentration